https://www.fiercebiotech.com/ en https://www.fiercebiotech.com/deals/best-biopharma-ma-deals In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years.   Jun 27, 2024 3:38pm Ayla Ellison, James Waldron, Annalee Armstrong https://www.fiercebiotech.com/a4d8cd1f-0da6-467e-a168-c6c3dcfd771a https://www.fiercebiotech.com/deals/burned-eu-backtrack-valneva-may-have-found-partner-fund-its-next-gen-shot European countries' decisions to backtrack on their large orders of Valneva’s COVID-19 vaccine appeared to have sunk the company’s hopes of developing a successor shot. But the French biotech is now teasing that it is in partnering talks it hopes will give it the financial security it needs to pursue this ambition. Sep 26, 2022 8:33am James Waldron https://www.fiercebiotech.com/59b42c46-3384-48aa-b039-6d1b6f46a8a0 https://www.fiercebiotech.com/deals/fda-hits-nuvations-solid-tumor-drug-hit-partial-hold-over-eye-inflammation-reports Nuvation’s slimmed down solid tumor strategy is already facing difficulties, with the FDA slapping a partial clinical hold on the biotech’s drug NUV-422 following reports of eye inflammation. Jun 27, 2022 9:35am James Waldron https://www.fiercebiotech.com/b6c24522-5184-4091-a782-e548589fd094 https://www.fiercebiotech.com/deals/taiho-claws-back-some-licensing-rights-its-lung-cancer-med-cullinan-atypical-frontloaded-deal Taiho is coughing up nearly $250 million in upfront cash to claw back some licensing rights of its licensing med originally handed off to Cullinan Oncology three years ago. The extension of the two companies' collaboration comes as the lung cancer med at the center of the dealmaking nears a pivotal phase 2 trial. May 11, 2022 6:21pm Max Bayer https://www.fiercebiotech.com/3d4448be-1958-4a6c-8235-9aed5aed2535 https://www.fiercebiotech.com/deals/nmd-pulls-40m-jeito-led-roche-backed-syndicate-gaining-financial-muscle-crack-myasthenia NMD Pharma has secured cash to muscle into the myasthenia gravis market. With Novo Holdings and Roche Venture Fund joining a syndicate led by Jeito Capital, the biotech has raised 35 million euros ($40 million) to take its lead candidate NMD670 through a phase 2a clinical trial in the indication. Feb 15, 2022 4:19am Nick Paul Taylor https://www.fiercebiotech.com/f5f9ac14-1c47-4b64-8aa3-732d22587dd2 https://www.fiercebiotech.com/deals/cardinal-health-forks-over-6-1b-for-three-medtronic-units Cardinal Health will acquire Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency units for $6.1 billion in cash in a deal slated to close in the quarter ending Sept. 30. Apr 18, 2017 10:44am Amirah Al Idrus https://www.fiercebiotech.com/ab250ead-686f-4c17-acf0-e76586e6169a https://www.fiercebiotech.com/deals/bristol-myers-nordic-bioscience-team-up-nash-biomarkers Bristol-Myers Squibb and Denmark’s Nordic Bioscience inked a deal to develop biomarker technology to diagnose and monitor fibrotic diseases such as nonalcoholic steatohepatitis (NASH). Apr 17, 2017 10:51am Amirah Al Idrus https://www.fiercebiotech.com/8a3f8478-6016-497e-b19c-eb3225bddb0e https://www.fiercebiotech.com/deals/wsj-a-twist-holmes-owes-theranos-25m Last month, reports unveiled a deal Theranos offered to investors, where CEO Elizabeth Holmes would give up shares from her personal stake in return for promises not to sue. Turns out Holmes is about $25 million in debt to her company. Apr 6, 2017 10:50am Amirah Al Idrus https://www.fiercebiotech.com/46753931-25ba-4283-9e2d-560b43946c72 https://www.fiercebiotech.com/deals/archerdx-helitec-partner-ngs-cancer-diagnostics-china Next-generation sequencing player ArcherDX and precision medicine company HeliTec are teaming up to develop NGS-based cancer diagnostics in China. The pair will work on NGS-based tech and aim to get cancer diagnostic kits through the CFDA. Apr 5, 2017 10:05am Amirah Al Idrus https://www.fiercebiotech.com/551486b2-7fa7-4375-b4ee-5cbbf8391c6f https://www.fiercebiotech.com/deals/philips-pathai-team-up-breast-cancer-dx Philips is partnering with PathAI, which is developing deep-learning algorithms for the detection and diagnosis of disease, to improve the speed and accuracy of cancer diagnosis. Their first focus will be breast cancer. Mar 31, 2017 11:03am Amirah Al Idrus https://www.fiercebiotech.com/663e8fcc-7aff-45c3-be48-2e1129b9a68e https://www.fiercebiotech.com/deals/boston-sci-to-drop-435m-swiss-heart-valve-maker Boston Scientific will pony up $435 million upfront to acquire Switzerland’s Symetis, which makes transcatheter aortic valve implantation devices. Mar 30, 2017 10:26am Amirah Al Idrus https://www.fiercebiotech.com/5a9c8e6d-c332-45fc-89ac-c4586621099a https://www.fiercebiotech.com/deals/viacyte-taps-gore-to-develop-delivery-devices-for-diabetes-cell-therapy ViaCyte, which is working on stem cell-based therapies for diabetes, has partnered with W.L. Gore to develop a delivery device for cell therapies that will protect the cells from being rejected by patients’ immune systems. Mar 28, 2017 1:52pm Amirah Al Idrus https://www.fiercebiotech.com/7de9d35b-fef1-47d2-b6d8-6649b1493b2b https://www.fiercebiotech.com/deals/medymatch-samsung-add-artificial-intelligence-to-stroke-dx-ambulances In its second partnership unveiled this month, Medymatch has inked a deal to integrate its decision-support technology with Samsung’s medical imaging machines in prehospital settings. Mar 28, 2017 10:07am Amirah Al Idrus https://www.fiercebiotech.com/0f01577c-5e9e-43bd-b2f4-0fbe5fbe312f https://www.fiercebiotech.com/deals/heat-to-buy-pelican-for-preclinical-cancer-pipeline Heat Biologics has struck a deal to buy a controlling stake in Pelican Therapeutics. The agreement will give Heat control of a preclinical immuno-oncology R&D program that is set to move an asset into phase 1 using some of the $15.2 million in grant funding Pelican secured last year. Mar 8, 2017 8:41am Nick Paul Taylor https://www.fiercebiotech.com/39b25539-957b-4009-b1ff-a0d7ffe51e6a https://www.fiercebiotech.com/deals/horizon-taps-amplycell-for-cell-line-optimization-tech Horizon Discovery has struck a deal to evaluate cell line optimization technology developed by Amplycell. The agreement sees Horizon pay an undisclosed upfront fee to evaluate the effect of the Amplycell technology on its glutamine synthetase null CHO K1 cell line. Mar 8, 2017 6:28am Nick Paul Taylor https://www.fiercebiotech.com/7606ba43-c018-446a-b6f6-b9578b675015 https://www.fiercebiotech.com/partnering/bioversys-aptuit-team-up-to-find-novel-antibiotic-targets Bioversys has enlisted Aptuit to support its efforts to identify and validate novel targets and drugs against Gram-negative bacteria. GlaxoSmithKline collaborator Bioversys is looking to Aptuit for drug discovery capabilities to support its own approach to overcoming antibiotic resistance. Mar 7, 2017 9:03am Nick Paul Taylor https://www.fiercebiotech.com/c580a73a-b273-4ae3-9f67-c9c240b4945f https://www.fiercebiotech.com/deals/via-surgical-pens-distribution-pact-for-hernia-surgery-device Via Surgical has signed up a U.S. distributor for its FasTouch surgical fixation system. The deal sees Progressive Medical sign up to distribute the Israeli medtech company’s FDA-cleared devices for fixing prosthetic material to soft tissue. Mar 6, 2017 10:06am Nick Paul Taylor https://www.fiercebiotech.com/a8166359-3827-4396-a982-74fa08a04578 https://www.fiercebiotech.com/deals/sanofi-pays-eu120m-to-buy-into-astrazeneca-rsv-program Sanofi has paid €120 million ($126 million) upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against respiratory syncytial virus (RSV). The agreement will see Sanofi and AstraZeneca equally share costs and profits for a phase 2b asset with the potential to immunize infants against a virus that kills 160,000 children a year. Mar 3, 2017 3:26am Nick Paul Taylor https://www.fiercebiotech.com/96dd9564-ad07-4fe1-be4e-8c2f79a9bef5 https://www.fiercebiotech.com/deals/advaxis-pens-backloaded-358m-cancer-delivery-tech-deal Advaxis has licensed its antigen delivery technology for use in Sellas’ cancer immunotherapy. The project will combine Advaxis’ approach to bioengineering bacteria to Sellas’ phase 3-ready WT1 antigens to foster more precise immune responses. Feb 27, 2017 7:59am Nick Paul Taylor https://www.fiercebiotech.com/3dd59bad-2cd5-4d48-9357-dc004e366d45 https://www.fiercebiotech.com/medical-devices/labcorp-to-acquire-lab-diagnostics-player-paml LabCorp agreed to acquire Pathology Associates Medical Laboratories from Providence Health & Services and Catholic Health Initiatives for an undisclosed amount. Feb 24, 2017 11:25am Amirah Al Idrus https://www.fiercebiotech.com/e951f10c-e60d-4a26-a0cc-c2021c0ab8d4 https://www.fiercebiotech.com/deals/takeda-to-trial-depression-monitoring-apple-watch-app Takeda has teamed up with Cognition Kit to trial the use of an Apple Watch app to monitor people with depression. The project will assess the feasibility and effectiveness of using wearable devices to track the mood and cognition of people with the condition. Feb 23, 2017 10:23am Nick Paul Taylor https://www.fiercebiotech.com/0f1f36e0-0f46-418d-8811-59d47a803ddb https://www.fiercebiotech.com/deals/cancer-player-nordic-nanovector-stokes-takeover-talk Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma candidate Betalutin. Costa claimed the level of interest in the asset is growing as clinical data accumulates, triggering a double-digit jump in Nanovector’s stock price. Feb 21, 2017 6:05am Nick Paul Taylor https://www.fiercebiotech.com/050580d5-6b67-4f54-9a95-2ee445d48879 https://www.fiercebiotech.com/deals/livongo-voluntis-partner-diabetes-management-offering Livongo Health has struck a deal to offer Voluntis’ insulin dose recommendation medical device as part of its diabetes management service. The partners hope to improve treatment adherence and dose optimization by delivering automated recommendations to Livongo members’ smartphones. Feb 17, 2017 8:29am Nick Paul Taylor https://www.fiercebiotech.com/02fdeaee-0abf-49fe-bebd-b11a80278f9a https://www.fiercebiotech.com/deals/gilead-sells-phase-2-addiction-drug-to-ex-cvt-team Gilead has sold a phase 2-ready addiction candidate to Amygdala Neurosciences. The deal returns control of the ALDH2 inhibitor to the team that was developing the asset before Gilead acquired it in its $1.4 billion takeover of CV Therapeutics. Feb 17, 2017 2:55am Nick Paul Taylor https://www.fiercebiotech.com/6c42ef0f-1936-4e76-85af-9eee647ffd2a https://www.fiercebiotech.com/deals/aeglea-raises-50m-ipo-after-slashing-share-price Austin, TX-based Aeglea BioTherapeutics raised $50 million in its IPO after pricing 5 million shares at $10 each, far below the range that it had set out for itself. Apr 7, 2016 9:48am John Carroll https://www.fiercebiotech.com/bddd53ee-279f-4a3c-b020-6574d80586ec